Avita Medical has been awarded an additional US$450 thousand from the US Armed Forces Institute of Regenerative Medicine (AFIRM) to expedite approval of the company's ReCell Autologous Spray On Skin in the US market. The award is in addition to the US$1.45 million granted to the former by the latter in May 2009.
Avita Medical CEO, Dr William Dolphin said, "The Department of Defense has recognized the major benefits which ReCell provides to patients and surgeons with improved outcomes and decreased morbidity. It should also result in significant reduction in costs to the healthcare system and third party payers with reduced hospitalization times and ongoing treatment costs."
Share this: 
Del.icio.us |
Email This | 
Printer Friendly
